Date: 2016-03-21
Type of information: Establishment of a new subsidiary in the US
Compound:
Company: Onxeo (France)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: establishment of a new subsidiary in the US
Action mechanism:
Disease:
Details: * On March 21, 2016, Onxeo announced the creation of a U.S. subsidiary, based in New York City. The company
also announced that experienced industry executive Philippe Maitre will head the U.S. subsidiary with the title of Executive VP & Chief of U.S. Operations. The U.S. subsidiary, to be named Onxeo US, will provide services to Onxeo as the company expands its development programs and establishes closer ties with the scientific and financial communities in the U.S. Philippe Maitre commented brings more than 35 years of experience in the pharmaceutical and biotech industry, including nearly 15 years as Corporate Officer for US public companies. Mr. Maitre has served as Chief Executive Officer and Co-Founder of mAbRx, a biotech company developing monoclonal antibodies against cancer stem cells in partnership with the Duke Cancer Center. Prior to founding mAbRx, Philippe has been the
Chief Executive Officer at Anosys, a cancer vaccine company spin-off from Aventis (today Sanofi). He has also served as a Chief Financial Officer for NASDAQ-listed companies Pharmaceutical Product Development Inc. (PPD Inc.) and Oscient Pharmaceuticals. Earlier in his career, Mr. Maitre served in various roles such as finance, business development and investor relations at companies Rhone Poulenc, Rhone Poulenc Rorer as well as Aventis, where he ultimately held the position of Senior Partner and Deputy CFO for Aventis Pharma Group.
Financial terms:
Latest news:
